4 research outputs found
Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients
Cannabis use disorder is frequent in schizophrenia patients, and it is associated with an earlier age of onset and poor schizophrenia prognosis. Serotonin 2A receptors (5-HT2AR) have been involved in psychosis and, like Akt kinase, are known to be modulated by THC. Likewise, endocannabinoid system dysregulation has been suggested in schizophrenia. The presence of these molecules in blood makes them interesting targets, as they can be evaluated in patients by a minimally invasive technique. The aim of the present study was to evaluate 5-HT2AR protein expression and the Akt functional status in platelet homogenates of subjects diagnosed with schizophrenia, cannabis use disorder, or both conditions, compared with age- and sex-matched control subjects. Additionally, endocannabinoids and pro-inflammatory interleukin-6 (IL-6) levels were also measured in the plasma of these subjects. Results showed that both platelet 5-HT2AR and the active phospho (Ser473)Akt protein expression were significantly increased in schizophrenia subjects, whereas patients with a dual diagnosis of schizophrenia and cannabis use disorder did not show significant changes. Similarly, plasma concentrations of anandamide and other lipid mediators such as PEA and DEA, as well as the pro-inflammatory IL-6, were significantly increased in schizophrenia, but not in dual subjects. Results demonstrate that schizophrenia subjects show different circulating markers pattern depending on the associated diagnosis of cannabis use disorder, supporting the hypothesis that there could be different underlying mechanisms that may explain clinical differences among these groups. Moreover, they provide the first preliminary evidence of peripherally measurable molecules of interest for bigger prospective studies in these subpopulations.Eusko Jaurlaritza, Grant/Award Numbers: 2019111082, IT1512/22, ITIT1211-19; Ministerio de Sanidad, Grant/Award Number: PNSD2019I021; Spanish Ministry of Science and Innovation, Grant/Award Number: PID2019-106404RB-I0
ISOLATION AND CHARACTERIZATION OF NEURONS AND GLIA FROM THE OLFACTORY NEUROEPITHELIUM OF SCHIZOPHRENIA SUBJECTS
DISCOVERING THE MOLECULAR MECHANISMS UNDERLYING CANNABIS-INDUCED INCREASED RISK OF SCHIZOPHRENIA: EVALUATION OF THE AKT/MTOR/S6 PATHWAY STATUS IN A DOUBLE HIT RODENT MODEL.
Isolation and Differentiation of Neurons and Glial Cells from Olfactory Epithelium in Living Subjects
The study of psychiatric and neurological diseases requires the substrate in which the disorders occur, that is, the nervous tissue. Currently, several types of human bio-specimens are being used for research, including postmortem brains, cerebrospinal fluid, induced pluripotent stem (iPS) cells, and induced neuronal (iN) cells. However, these samples are far from providing a useful predictive, diagnostic, or prognostic biomarker. The olfactory epithelium is a region close to the brain that has received increased interest as a research tool for the study of brain mechanisms in complex neuropsychiatric and neurological diseases. The olfactory sensory neurons are replaced by neurogenesis throughout adult life from stem cells on the basement membrane. These stem cells are multipotent and can be propagated in neurospheres, proliferated in vitro and differentiated into multiple cell types including neurons and glia. For all these reasons, olfactory epithelium provides a unique resource for investigating neuronal molecular markers of neuropsychiatric and neurological diseases. Here, we describe the isolation and culture of human differentiated neurons and glial cells from olfactory epithelium of living subjects by an easy and non-invasive exfoliation method that may serve as a useful tool for the research in brain diseases.Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study was funded by the Spanish Ministry of Science and Innovation (PID2019-106404RB-I00), Spanish Ministry of Health (PNSD 2019I021), and Basque Government (2019111082, IT1211/19 and IT1512/22)